Overview :
1. Merck was founded in 1668
2. Globl drug manufacture in the world
3. Merck’s significant investment in internal research and development (R&D) was a strategic advantage with which few companies could compete
4. Merck’s recent $41 billion “reverse-merger” with Schering-Plough represented a significant step away from a closed R&D model toward a more open innovation strategy. Merck is a global research-driven company that discovers, develops, manufactures, and markets a broad range of innovative products to improve human and animal health.
5. They call The Harvard Pharma, because By 1950, five Merck researchers had won Nobel prizes for their contributions to medicine. Head scientists were successful in the recruitment and retention of superior research personnel because Merck maintained an academic, university-like atmosphere in which scientists were given freedom to explore their personal research interests.
6. Fosamax drugs revention of osteoporosis
7. Recall drugs vioxx
8. The joining of these two former rivals in March 2009 was seen as a necessary step toward diversification and increased economies of scale, propelled by imminent patent expirations and increasing pressure from shareholders, government, and customers to control costs.
9. The deal was structured as a “reverse-merger” to permit SP to bypass a change-of-control clause in a drug partnership it had with Johnson & Johnson (J&J). SP and J&J shared the rights to the blockbuster drugs Remicade and Simponi,
10. Merck didnt get the product of J & J with SP
11. Mass merger
12. FDA costly and lenght
13. The rapid rise of the biotechnology industry seemed to promise a solution to the R&D drought in pharmaceutical companies’ pipelines, attracting more than $40 billion of venture capital to date.
14. However, biotechnology has hardly been the hoped-for panacea for the pharmaceutical